Posted by Michael Wonder on 26 Aug 2021
Servier announces FDA approval of Tibsovo (ivosidenib tablets) in IDH mutated cholangiocarcinoma
25 August 2021 - TIBSOVO is the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma.
Servier Pharmaceuticals announced today that the U.S. FDA approved Tibsovo (ivosidenib tablets) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA approved test.
